Shree Ganesh Remedies Ltd
Shree Ganesh Remedies is engaged in the business of Pharma Intermediate.
- Market Cap ₹ 1,097 Cr.
- Current Price ₹ 855
- High / Low ₹ 935 / 380
- Stock P/E 39.0
- Book Value ₹ 95.4
- Dividend Yield 0.06 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 35.1% CAGR over last 5 years
Cons
- Stock is trading at 8.91 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | |
|---|---|---|---|---|
| 35 | 64 | 49 | 126 | |
| 26 | 52 | 35 | 84 | |
| Operating Profit | 9 | 13 | 14 | 42 |
| OPM % | 25% | 20% | 28% | 33% |
| 1 | 4 | 2 | 3 | |
| Interest | 0 | 1 | 0 | 1 |
| Depreciation | 1 | 2 | 3 | 6 |
| Profit before tax | 9 | 14 | 13 | 38 |
| Tax % | 28% | 23% | 25% | 26% |
| 6 | 10 | 10 | 28 | |
| EPS in Rs | 4.88 | 8.18 | 7.62 | 21.96 |
| Dividend Payout % | 18% | 13% | 18% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 37% |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 42% |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 75% |
| 3 Years: | 39% |
| 1 Year: | 90% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | |
|---|---|---|---|---|
| Equity Capital | 9 | 9 | 13 | |
| Reserves | 25 | 33 | 109 | |
| 1 | 4 | 36 | ||
| 7 | 9 | 12 | ||
| Total Liabilities | 41 | 55 | 171 | |
| 14 | 20 | 81 | ||
| CWIP | -0 | -0 | 17 | |
| Investments | 4 | 3 | 5 | |
| 23 | 32 | 69 | ||
| Total Assets | 41 | 55 | 171 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | |
|---|---|---|---|---|
| -5 | 5 | 3 | 30 | |
| -0 | -3 | -1 | -33 | |
| -0 | -0 | -1 | 10 | |
| Net Cash Flow | -5 | 1 | 2 | 7 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 101 | 101 | 59 | |
| Inventory Days | 125 | 61 | 159 | |
| Days Payable | 75 | 43 | 52 | |
| Cash Conversion Cycle | 151 | 119 | 166 | |
| Working Capital Days | 149 | 115 | 123 | |
| ROCE % | 35% |
Business segments[1]
Pharmaceutical intermediates: 32+ products; 54 Cr sales in FY23 (vs 51 Cr in FY22)
Human pharma segments: Antipsychotic, Antidepression, Oncology, Diabetic, Diuretic
Veterinary segment: Feed Additives, Antiparasitic, Anti-Inflammator
Fine and Specialty Chemicals: 11+ products; 37 Cr. sales in FY23 (vs 20 Cr. in FY22)
Industries served: Aroma & Health, Agrochem, Polymer, Electronics